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Background: Monogenic gain-of-function protein aggregation diseases, including Huntington’s disease, exhibit
substantial variability in age of onset, penetrance, and clinical symptoms, even between individuals with similar or
identical mutations. This difference in phenotypic expression of proteotoxic mutations is proposed to be due, at
least in part, to the variability in genetic background. To address this, we examined the role of natural variation in
defining the susceptibility of genetically diverse individuals to protein aggregation and toxicity, using the
Caenorhabditis elegans polyglutamine model.
Results: Introgression of polyQ40 into three wild genetic backgrounds uncovered wide variation in onset of
aggregation and corresponding toxicity, as well as alteration in the cell-specific susceptibility to aggregation. To
further dissect these relationships, we established a panel of 21 recombinant inbred lines that showed a broad
range of aggregation phenotypes, independent of differences in expression levels. We found that aggregation is a
transgressive trait, and does not always correlate with measures of toxicity, such as early onset of muscle
dysfunction, egg-laying deficits, or reduced lifespan. Moreover, distinct measures of proteotoxicity were
independently modified by the genetic background.
Conclusions: Resistance to protein aggregation and the ability to restrict its associated cellular dysfunction are
independently controlled by the natural variation in genetic background, revealing important new considerations in
the search for targets for therapeutic intervention in conformational diseases. Thus, our C. elegans model can serve
as a powerful tool to dissect the contribution of natural variation to individual susceptibility to proteotoxicity.
Please see related commentary by Kaeberlein, http://www.biomedcentral.com/1741-7007/11/102.
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A number of very serious human disorders are characte-
rized by the appearance of protein aggregates, including
neurodegenerative diseases such as Huntington’s disease
(HD), metabolic disorders, and certain developmental
disorders [1,2]. Hereditary forms of these diseases are
caused by de novo gain-of-function mutations that result
in expression of destabilized, aggregation-prone proteins
[3,4], accompanied by the disruption of protein-folding* Correspondence: tg443@drexel.edu
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reproduction in any medium, provided the orhomeostasis (proteostasis) and cellular dysfunction [5-11].
Although these mutations themselves are causative, many
disease characteristics such as age of onset, penetrance,
and severity of specific symptoms can vary widely between
individuals. For example in HD, the age of neurological
onset is strongly associated with the length of poly-
glutamine (polyQ) expansion in huntingtin protein. Yet
age of onset can vary by several decades in people carrying
the same length polyglutamine expansion, and a large pro-
portion of this residual variation is genetic in nature and
may be due to polymorphisms in other genes [12-15]. This
variability is also seen in animal models of disease; for
example, different genetic backgrounds of common labo-
ratory mouse strains differentially modify somatic CAG
repeat expansion and the onset of nuclear accumulationral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[16-18]. It is generally well appreciated that genetic vari-
ation influences the phenotypic expression of mutations
and transgenes, and the effects of environmental pertur-
bations [19-23]. However, the nature of modifying alleles
segregating in populations remains elusive for protein
conformational diseases [15,24].
Much of the current knowledge about modifiers of
conformational diseases has been gathered from linkage/
association studies, candidate approaches, and unbiased
genetic screens. The latter two approaches often use in-
duced mutations, including knockouts/knockdowns and
overexpression, in fixed genetic backgrounds. Although
genetic variants identified in this way are enormously
informative about pathways that affect disease processes
and that can, when perturbed, modify disease pheno-
types [25-30], they are likely to be different from the
naturally occurring variations. First, these approaches
are designed to identify individual modifier genes with
strong phenotypic effects. By contrast, a naturally occur-
ring genetic variation, in addition to the singleton genes
with strong effect, is likely to be represented by complex
networks of interactions of multiple common variants
with small effects, and/or of rare or even private alleles
with larger contributions [31-37], as well as cryptic
genetic variation [38-40], thus making association of
phenotypic differences with their underlying genotypes
very challenging. Protein aggregation diseases present an
additional unique challenge, owing to the sheer number
of different processes and pathways that control pro-
teostasis [30,41-43]. Modulation of proteostasis has been
shown to buffer the expression of certain mutations and
coding polymorphisms into phenotypes. For example,
expression of aggregation-prone polyQ and SOD1 pro-
teins [5,6], or down-modulation in plants and animals
of activity of molecular chaperones, such as heat shock
protein 90 (HSP90), unmasks buffered phenotypes
caused by mildly destabilizing mutations segregating in
populations [44-48], a phenomenon similar to the heat-
induced phenocopies [49,50]. At the same time, the
presence of such mild destabilizing variants in the
genetic background modulates the aggregation and tox-
icity of aggregation-prone proteins, including polyQ
[5,6]. An additional consideration in protein confor-
mation diseases is the possibility of certain induced mu-
tations, especially knockouts/knockdowns, to imbalance
the proteostasis directly, for example by targeting a
member of a multimeric complex and inducing a folding
stress in the cell. Because imbalance in proteostasis
can indirectly affect the aggregation phenotype of the
disease-causing mutation, such genetic intervention may
appear as a true modifier.
Secondly, because natural variants have been acted
upon by selection, they are largely compatible withnormal organismal development and function [23], in
contrast to many of the modifiers of the induced-
mutation type, which are not phenotypically innocuous.
Moreover, genetic manipulations that protect cells and
organisms from the toxic effects of protein aggregation
can themselves be deleterious to the organism; many of
the lifespan-extending mutations protect against pro-
teotoxicity, but are incompatible with normal develop-
ment, or are maladaptive under competitive conditions
[51-53]. Similarly, overexpression of molecular cha-
perones or heat shock factor, which consistently protects
against proteotoxicity, can be accompanied by slow
growth and development, decreased fecundity, and aber-
rant signaling, and may even support transformed phe-
notypes [54-57]. Thus, identifying proteostasis modifiers
from among natural variants shaped by selection may
pinpoint the potential genes and networks that are
naturally plastic [23] and thus can be pharmacologically
modulated without negative effects on the organism.
In contrast to induced-mutation approaches, asso-
ciation studies do look at natural variants. However, the
complexity of the genetic variation involved in control
of proteostasis, as discussed above, makes these studies
very difficult. Indeed, only a small number of genes have
been firmly identified as modifiers of aggregation
diseases by either candidate or association approaches
[15,24]. Furthermore, these modifiers are often not repli-
cated in different populations, and replicated modifiers
account for only a small fraction of the heritable vari-
ation [15,58-60]. Genetic tractability of model animals,
together with the ability to control the contribution of
the environment, offers a unique opportunity to examine
how natural variation in the genetic background of indi-
viduals affects their ability to resist protein aggregation;
what is the nature of the genetic variants that modify
proteostasis; whether these are distinct from the
spectrum of induced mutations; and whether natural
variation can predict/modify the susceptibility to protein
conformation diseases.
Recombinant inbred lines (RILs) have been used
successfully, from yeast to mice, to answer similar ques-
tions about non-transgenic physiological traits, includ-
ing complex traits [18,61-66]. Here we established the
polyglutamine transgenic Caenorhabditis elegans as one
such model, taking advantage of the availability of
genetically diverse wild isolates, and the ability to detect
and measure protein aggregation in a live animal
throughout its lifespan. In addition to the short gene-
ration time and lifespan of C. elegans, and the wealth of
knowledge and reagents available for the pathways
known to modulate aging and proteostasis, the facul-
tative sexual reproduction mode of this organism allows
for multifactorial perturbation of genetic variants through
outcrossing, combined with the capture of true-breeding
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for future mapping of the natural modifier alleles of pro-
tein aggregation and toxicity.
Results
Genetic background modulates age of onset and
cell-specific susceptibility to polyQ aggregation
As described previously, expression of the near-threshold
yellow fluorescent protein (YFP)-tagged polyglutamine ex-
pansion polyQ40-YFP (Q40) in muscle cells of C. elegans
shows a striking age-dependent onset of aggregation, re-
gulated by heat shock factor 1 (HSF1) and the insulin sig-
naling pathway [25,26,67]. However, unlike the variability
of polyQ-associated disease phenotypes in the human
population, the behavioral, biochemical, and aggregation
phenotypes in the C. elegans laboratory Bristol (N2) strain
are homogeneous. To investigate whether natural genetic
variation in C. elegans modifies polyQ aggregation and
associated phenotypes, we introgressed the polyQ40Figure 1 Genetic background separately regulates polyQ aggregation
background. The Q40 transgene is integrated on chromosome X. (b) Early
larvae were scored, 10 animals each. (c) Comparison of number of polyQ a
represents an individual animal, at least 16 animals per genotype. (d) Distri
Q40Bristol and (2) Q40DR1350 animals. Lower panels show magnification o
induced decrease in muscle function. Swimming motions (bends per minu
indicated genotypes, 30 to 45 animals for each genotype. (c,e,f) Data were
test, α = 0.01, ***P<0.001. (b) Data were analyzed by unpaired t-test, two-tatransgene from the Bristol background into three wild
strains: a California-derived isolate DR1350, the Madeira
isolate JU258, and a genetically distant Hawaii isolate
CB4856 [68]. The introgression approach ensures that the
transgene is present in the same copy number and ge-
nomic location in each of the resulting strains (Figure 1a),
while long-term backcrossing (>35 generations) ensures a
high degree of genetic homogeneity within each strain.
PolyQ aggregation and toxicity was strongly affected by
introgression into wild strains. We observed an early onset
of aggregation in DR1350 background, with on average
eight-fold higher number of aggregates in the second lar-
val stage (L2) of Q40DR1350 animals than in Q40Bristol
animals (Figure 1b), and a twofold to threefold increase at
the late larval stage 4 (L4) (Figure 1c, and data not shown).
These early onset and increased aggregation were not due
to any changes in polyQ40 expression (Figure 2d). By con-
trast, the Hawaii and Madeira backgrounds had only mild
effects on polyQ aggregation (Figure 1c).and toxicity. (a) Introgression of Q40 locus from Bristol to DR1350
onset of aggregation in DR1350 relative to Bristol background. Late L2
ggregates per L4 animal in different backgrounds. Each symbol
bution of polyQ aggregates in muscle cells in young adult (1)
f the selected regions, arrow indicates head muscles. (e,f) PolyQ-
te) were scored for (e) day 2 or (f) day 3 adult animals of the
analyzed by ANOVA followed by Bonferroni’s multiple comparison
iled, with Welch’s correction, P<0.0001.
Figure 2 Multiple alleles control polyQ aggregation in Caenorhabditis elegans. (a) Scheme of generation of Q40Bristol × DR1350
recombinant inbred lines (RILs). To ensure genetic homogeneity within each RIL, 30 to 40 generations of self-reproduction were used.
(b) Number of polyQ aggregates per L4 animal of parental strains and 21 RILs. Data are mean ± SD, 17 to 23 animals/data point. Colors
correspond to selected strains as indicated in supplementary material (see Additional file 2: Figure S2a). (c) Images of representative animals used
in (b); insets show head regions. (d) Western blotting analysis of total Q40-YFP protein levels in extracts of L3 animals, relative to Q40Bristol. Data
are mean ± SD, n = 3.
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polyQ aggregation was markedly different between the
Bristol and DR1350 backgrounds. Head muscle cells were
more resistant to aggregation than body wall muscles in
Q40Bristol animals, whereas the inverse was true in the
Q40DR1350 animals, with the head muscles exhibiting
the earliest onset of polyQ aggregation. The head muscle
cells of L2/L3 Q40DR1350 animals contained 74 ± 4% of
all aggregates, compared with 22 ± 12% for Q40Bristol
animals (mean ± SEM, n = 10). The Q40DR1350 strain
retained this cell type-preferential aggregation phenotype
throughout development (Figure 1d). The allele or alleles
that confer increased susceptibility of this subset of muscle
cells to aggregation appear to be unique to these two
strains, as neither the Q40Hawaii nor Q40Madeira strains
exhibited this phenotype.Genetic background differentially modulate polyQ
aggregation and toxicity
Consistent with the earlier onset of aggregation, the
Q40DR1350 strain exhibited an earlier onset of toxicity,
with a twofold to threefold reduction in mean motility
relative to Q40Bristol animals at days 1 to 3 of adult-
hood (Figure 1e,f; see Additional file 1: Figure S1a). This
was in contrast to the Hawaiian background where
this relationship was inverted, and reduced and delayed
toxicity was apparent despite slightly increased aggre-
gation. The Q40Hawaii strain had on average twofold
improved motility relative to Q40Bristol on day 2 of
adulthood, and this protection against polyQ toxicity
was further enhanced to fivefold on day 3 of adulthood
(Figure 1e,f ). These results reveal that the Hawaiian
background is highly protective against the toxic effects
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visual appearance of aggregates (Figure 1c). This demon-
strates that genetic polymorphisms that are present in
the wild strains, and, therefore, acted upon by selection,
are able to separately regulate the aggregation and
resulting toxicity of polyglutamine protein. Thus, the
genetic variants present in outbred populations provide
natural protection against, or susceptibility to, protein
aggregation and toxicity.
Multiple alleles control polyQ aggregation in C. elegans
Because introgression of the polyQ40 transgene into dif-
ferent genetic backgrounds revealed the presence of
natural variation in both aggregation and associated toxi-
city, we tested whether these phenotypes are controlled by
the same or distinct genetic networks. To address this,
we established a panel of RILs, each carrying the same
polyQ40 transgene in the same genomic location, using
the two backgrounds, that were most divergent for these
phenotypes: Bristol and DR1350 (Figure 2a). Although
each RIL carried a randomly generated assortment of
parental alleles, the long-term inbreeding of each RIL
ensured within-line homogeneity. This approach allowed
for separation in the progeny of alleles that act epistatically
or in concert in parental backgrounds, and for new confi-
gurations of genetic networks.
The 21 RILs exhibited a wide range of phenotypes
from delayed onset and suppressed extent of aggregation
in RILs 16 and 9, to strongly enhanced aggregation in
RILs 12(2) and 15 (Figure 2b,c). RILs 15 and 16 showed
transgressive behavior, with the number of aggregates in
the majority of animals (88% for RIL 15 and 100% for
RIL 16) being more than 2SD away from the mean of
either of the parental lines, indicating contributions from
multiple modifier alleles. The onset and extent of pro-
tein aggregation can be dependent on the expression
levels, and we have previously reported delay in onset of
aggregation in animals heterozygous for polyQ40 [5]. To
address this, we measured polyQ-YFP fluorescence levels
in extracts of L1 larva, prior to onset of aggregation, to
determine whether it correlated with aggregation, and
found no correlation between expression levels and
aggregation of polyQ protein in RILs (R2 = 0.055) (see
Additional file 2: Figure S2a).
We further selected several RILs with similar expression
levels, which were either most suppressed or most
enhanced in terms of aggregation, and two RILs whose
aggregation was similar to each of the parental lines
(Figure 2b, colored bars; see Additional file 2: Figure S2b),
resulting in five RILs and two parental lines binned into
four aggregation groups. Similar polyQ expression levels
in these strains were confirmed by measuring total polyQ-
YFP protein levels in L3 animals by western blotting ana-
lysis, showing that neither enhancement (RILs 12(2) and15), nor suppression (RIL 16) of aggregation in these
selected lines was due to a change in expression levels of
polyQ protein (Figure 2d). Furthermore, increased (RIL 2)
or decreased (RIL 16) aggregation as detected by visual
appearance of fluorescent foci in day 1 adult animals cor-
related with increased or decreased levels of polyQ protein
in the SDS-resistant high molecular weight fraction (see
Additional file 2: Figure S2c). Thus, polyQ aggregation
appears to be a transgressive trait, with some RIL progeny
occupying phenotypic extremes relative to the parental
strains (Figure 2b), indicating that multiple alleles with
opposing or epistatic effects control protein aggregation.
Natural variation independently controls resistance to
aggregation and the ability to restrict its associated
cellular dysfunction
In both parental lines, we found expression of the
aggregation-prone polyQ40 to be associated with mus-
cle toxicity (Figure 1e,f; see Additional file 1: Figure S1).
Thus, we investigated whether natural variants segrega-
ting in the RIL progeny population were coordinately
regulating polyQ aggregation and toxicity. We reasoned
that RILs with enhanced aggregation would show earlier
or more severe organismal correlates of polyQ toxicity,
and vice versa. To monitor toxicity phenotypes, we scored
motility and egg-laying, traits that directly report on the
dysfunction of two different muscle subtypes, namely,
body wall and reproductive muscles. We also scored
shortening of the lifespan, which is a more indirect mea-
sure of organismal dysfunction caused by expression of
polyQ40 in the muscle cells. The ability to simultaneously
score these different toxicity measures in the same ani-
mals allows comparison of cell type-selective and global
consequences of polyQ toxicity.
Motility was measured by adapting a population-level
muscle dysfunction index (MDI; see Methods), that re-
ports on the gradual deterioration of movement over the
lifespan [69] (Figure 3a). We found that the MDI overall
tracked with enhanced or suppressed aggregation for the
five RILs scored (Figures 2b, 3a, 4b). For example, RIL
16 exhibited the lowest level of aggregation (ranked 1
for aggregation, see Additional file 2: Figure S2b) and
was the most protected of the polyQ40-containing lines
(ranked 1 for MDI, Figures 3a and 4b), whereas RIL 15
had early onset of both aggregation and muscle dysfunc-
tion. However, there was not an absolute corres-
pondence in relative ranking: RIL 12(2), representing the
most enhanced aggregation bin (ranked 6 to 7, see
Additional file 2: Figure S2b), had a similar time to onset
of muscle dysfunction as the much less aggregating RIL
10 (Figures 3a, 4b), indicating that variants present in
RIL 12(2) protected muscle cells from the toxic effects
of polyQ aggregation, but not from the protein aggrega-
tion itself. Two of the RILs examined, RILs 16 and 10,
Figure 3 Large variation in toxicity correlates. (a) Progressive
increase in muscle dysfunction index (MDI) during adulthood and
aging of indicated strains: MDI is 1 when all animals on the plate move
spontaneously, and MDI is 3 when all are paralyzed. The curves are a
rolling average with a period of 2 days. (b) Internal hatching (bagging)
phenotype due to dysfunction in reproductive muscles, scored over
the entire egg-laying period. Data are mean ± SD, at least 30 animals
per trial, n = 3 trials.
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transgenic Bristol and DR1350 strains and the parental
Q40Bristol and Q40DR1350 strains (Figure 3a). Thus,
polyglutamine aggregation and the associated muscle
dysfunction are both controlled by complex but non-
overlapping allelic variation present in C. elegans strains.
Shortening of lifespan also showed incomplete corres-
pondence with enhanced or suppressed aggregation. The
reduced aggregation RILs 16 and 10 had the longest life-
span (approximately 18.6 and 17 days, respectively) of
the seven strains scored (Table 1; Figure 4a). However,
the highest aggregating RIL 15 had only intermediate
shortening of the lifespan. Furthermore, although
Q40DR1350 and RIL 2 belonged to the same aggrega-
tion bin (see Additional file 2: Figure S2b), they had very
disparate shortening of the lifespan (approximately 17
and 13.5 days, respectively) (Table 1), with one having a
shorter and one a longer lifespan than that predicted by
the aggregation rank (Figure 4a).Because progressive muscle dysfunction in C. elegans
has been linked to aging [69], we compared the lifespan
and MDI ranking of the same animals, and found that
polyQ toxicity measured by muscle dysfunction could
be uncoupled from the shortening of the lifespan. For
example, relative to its aggregation rank, Q40DR1350
had a high degree of muscle dysfunction (ranked seventh
out of seven in MDI; Figure 3a), but only mild shor-
tening of lifespan (approximately 17 days, second out of
seven (Figure 4c; Table 1). Overall, these data showed
that in some genetic backgrounds there is corres-
pondence between aggregation, cellular dysfunction, and
lifespan, whereas other backgrounds appear to contain
non-overlapping variation that uncouples aggregation
from one or both measures of toxicity.
Finally, we scored an internal hatching phenotype
(‘bag of worms’; bag) that reports on the function of re-
productive muscle cells (Figure 3b). Unexpectedly, we
found that the expression of polyQ40 caused significant
toxicity in the reproductive tract, irrespective of the
overall aggregation status (for example, compare RIL 16
and RIL 2; Figures 2b and 3b). The bag phenotype was
undetectable or was only at background levels in the
first 3 days of the reproduction period, suggesting that it
was degenerative in nature and not due to a defect in
muscle development. Thus, it appears that not only it is
possible to uncouple aggregation and toxicity through
the influence of natural genetic variation in C. elegans,
but there are also intrinsic differences in the relative
sensitivity of muscle cell types to the expression of
polyglutamine expansion.
Discussion
Our studies establish C. elegans as a potent model to
probe the natural variation that shapes the susceptibility
of individual animals to the toxic effects of protein
aggregation. We found that three of the wild back-
grounds used in this study had modifying effects on
multiple aspects of polyglutamine aggregation and toxi-
city, including the onset and extent of aggregation, the
differential susceptibility of specific subsets of muscle
cells to aggregation, and the direct cellular and indirect
organismal correlates of dysfunction. Another important
finding in this model is that both polyQ aggregation and
toxicity behaved as complex traits, suggesting that mul-
tiple additive or interacting alleles from wild C. elegans
backgrounds are contributing to this phenotypic va-
riation. Thus, this model will provide an invaluable tool
to investigate the nature of alleles that contribute to the
robustness of proteostasis in genetically diverse but
phenotypically normal individuals.
Much progress has been made in understanding the
mechanisms by which protein misfolding and aggre-
gation causes cellular toxicity, and the pathways and
Figure 4 Genetic background determines resistance and tolerance of polyQ aggregation. (a,b) Relative ranking of indicated polyQ-carrying
strains in aggregation and two toxicity correlates: (a) abnormally short lifespan and (b) muscle dysfunction. Aggregation ranking is as described
in supplementary materials (see Additional file 2: Figure S2b). Strains that are paired share aggregation rank, and RIL 16 is unpaired. Placement
above or below the diagonal indicates decreased or increased tolerance, respectively. (c) Variation in polyQ aggregation tolerance measured by
shortening of lifespan could be separated from that measured by muscle dysfunction. DR1350 is indicated as an example of decreased tolerance
in terms of muscle dysfunction relative to lifespan.
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because the common candidate approaches (mutational,
knockout/RNA interference (RNAi), or overexpression)
are designed to detect genes that individually have large
phenotypic effects, they often identify modifier genes that
are not easy targets for intervention. Many of the genes
identified as important for maintenance of proteostasis,
including molecular chaperones, regulators of stress res-
ponses, insulin signaling, and autophagy, are themselves
either essential, or have additional strong effects on deve-
lopment and/or normal physiology [54,55,57]. Neverthe-
less, modifier backgrounds do exist in the outbred human
population, as evidenced by the large variability in age of
onset or even penetrance of protein misfolding diseases.
This suggests that natural genetic variants that are shaped
by selection can both provide protection against protein
aggregation and toxicity, and, at the same time, becompatible with normal development and physiology.
Thus, natural variation may tag the genetic and molecular
pathways whose inherent plasticity allows for development
of intervention strategies without the negative or toxic
effects.
Previous mutational studies have shown that protein
aggregation can be uncoupled from toxicity [73]. For
example, decreased insulin signaling causes increased
aggregation but decreased toxicity of Aβ in C. elegans
[74], whereas overexpression of HSP70 rescues polyQ
toxicity in Drosophila by affecting the properties but not
the extent of aggregation [75,76]. These studies suggest
that changing the aggregation pathway may translate
into changes in toxicity; however, the question remains
whether the two are always related causally, or whether
they are controlled by molecular pathways that can be
modified independently of each other. Studies of plant-
Table 1 Lifespan analysis
Name Number Restricted mean Age in days at percentage mortality 95%
median
CI
Days SEM 95% CI 25% 50% 75% 90% 100%
daf-16 119 16.17 0.51 15.16 to 17.18 13 15 19 22 31 14 to 15
age-1 107 29.57 1.62 26.39 to 32.75 17 27 42 50 53 22 to 30
Bristol 100 19.92 0.84 18.26 to 21.57 13 21 25 29 31 19 to 21
DR1350 123 22.75 0.85 21.09 to 24.41 21 23 26 28 34 21 to 25
Q40Bristol 120 14.89 0.46 13.98 to 15.80 11 15 17 20 28 15 to 15
Q40DR1350 102 18.32 1.06 16.24 to 20.39 12 18 25 26 28 15 to 22
Q40DR1350 40 16.53 0.99 14.59 to 18.48 12 17 22 23 24 15 to 19
RIL 2 100 13.6 0.54 12.54 to 14.67 12 13 16 19 21 13 to 14
RIL 2 102 13.49 0.49 12.53 to 14.45 11 13 17 18 26 12 to 12
RIL 10 117 17.33 0.51 16.33 to 18.34 15 17 20 23 28 15 to 17
RIL 12(2) 100 13.5 0.59 12.35 to 14.64 10 14 18 19 23 12 to 14
RIL 12(2) 116 14.66 0.34 13.99 to 15.33 12 15 17 19 26 14 to 14
RIL 15 70 15.69 0.91 13.90 to 17.48 12 15 18 21 26 14 to 17
RIL 15 111 14.81 0.68 13.49 to 16.14 12 15 17 21 33 12 to 14
RIL 16 91 18.6 1.11 16.43 to 20.76 14 19 23 25 26 15 to 22
RIL 16 115 18.65 0.99 16.70 to 20.60 15 17 23 28 27 15 to 19
RIL, recombinant inbred line.
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resistance (ability to limit pathogen burden) and tole-
rance (ability to limit fitness loss at a given pathogen
load) can have distinct genetic bases, and that genetic
variation exists for both [77,78]. We suggest that a simi-
lar logic could be applied to proteotoxic mutations. We
found that identical genetic lesions (the same transgene
introgressed into different strains) produced vastly dif-
ferent aggregation phenotypes, supporting variation in
resistance to aggregation, including at the level of cell
type-specific resistance in head versus body wall muscle
cells. At the same time, strains that exhibited similar
levels of polyQ aggregation differed widely in toxicity
correlates, such as muscle dysfunction and shortening of
lifespan. Although further research will be needed to
characterize these phenomena, these findings indicate a
remarkable variation at the organismal level in the ability
to tolerate protein aggregation. This is clearly evident in
natural isolates of C. elegans, as the Hawaiian strain
showed increased tolerance of polyQ aggregation as
measured by the loss of motility, whereas DR1350
showed both decreased resistance and decreased tole-
rance in terms of muscle dysfunction, but increased
tolerance when measured by the shortening of lifespan.
Furthermore, it appears that natural variants contri-
buting to resistance and tolerance can be found even
within the limited RIL panel used in this study; relative
to the parental strains, RIL 16 demonstrated remarkable
resistance and tolerance, the latter in both of the pheno-
typic measures for which variation was present.Our data thus reveal that distinct genetic networks
control protein aggregation and the various cellular and
organismal consequences of such aggregation. One po-
tential scenario for this distinction is that pathways that
affect resistance to aggregation act directly on the mu-
tant aggregation-prone protein, for example, by chan-
ging its folding trajectory or degradation rate, whereas
those that affect tolerance of protein aggregates also
affect specific cellular pathways that are disrupted in
disease, or affect parallel or compensatory pathways.
This suggests that, depending on the individual’s genetic
background, disease intervention strategies may need to
distinguish between the strategy of prevention of mis-
folding and aggregation from an alternative strategy of
strengthening specific cellular pathways that mediate
disease phenotypes.
Conclusions
These results establish C. elegans as a potent model to
study how natural variation shapes the susceptibility to
proteotoxicity in genetically diverse but phenotypically
normal individuals, and support the view that intrinsic
aggregation propensity of the mutant disease-related
proteins is not, by itself, sufficient to explain disease on-
set and phenotypes. We found that both protein aggre-
gation and toxicity behave as complex traits, suggesting
that multiple additive or interacting alleles contribute to
the variation in these phenotypes. The ability of standing
genetic variation in wild isolates of C. elegans to inde-
pendently modify the age of onset, the cell type-specific
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pendent toxicity correlates of the polyglutamine expan-
sion, suggests not only multiple paths to the expression
of toxicity, but also multiple potential routes of interven-
tion. Because natural variation represents genetic and
molecular pathways that are inherently plastic, identi-
fying these pathways will allows for development of in-
tervention strategies that avoid the negative or toxic
effects.
Methods
Nematode strains and growth conditions
Nematodes were grown at 20°C on nematode growth
medium (NGM) plates seeded with Escherichia. coli
OP50 [79]. Animals were synchronized by picking the
pre-comma stage embryos onto fresh plates, or by hypo-
chlorite treatment. Wild C. elegans strains were ob-
tained from the Caenorhabditis Genetic Center. The
Q40Bristol strain is AM737. To introgress Q40-YFP
transgene into the wild backgrounds, Q40Bristol males
were mated with DR1350, JU258(Madeira), or CB4856
(Hawaii) hermaphrodites, then five to seven F1 fluores-
cent hermaphrodites were mated with wild males, and
this two-step cycle was repeated until over 35 gene-
rations of backcrosses to the wild background were
reached. At this point, strains were homozygosed for
polyQ40 and cryopreserved. To generate RILs, fluores-
cent F2 animals from a cross between Q40Bristol males
and DR1350 hermaphrodites were singled out and
allowed to self-reproduce for 30 to 40 generations, by
transferring 25 to 30 L4 hermaphrodites to new plates
per generation. Strains were cryopreserved every 10 to
15 generations, and homozygosed for Q40 after gene-
ration 10. For RNAi experiments, nematodes were cul-
tured on control (L4440 empty vector, GeneService,
USA) or YFP RNAi plates from early embryo stage.
NGM plates containing 100 μg/ml ampicillin, 0.4 mol/l
isopropyl β-D-1-thiogalactopyranoside (IPTG) and 12
μg/ml tetracycline (Sigma) were spotted with overnight
RNAi bacterial cultures, and incubated for 2 days prior
to embryo plating. YFP RNAi resulted in a strong de-
crease in polyQ-YFP levels in Q40Bristol, and a weaker
decrease in Q40DR1350.
PolyQ aggregation
Except for one experiment (shown in Figure 2b), the
number of aggregates per animal was scored by coun-
ting fluorescent foci in live animals, using stereomicro-
scopes (MZ16FA or M205FA; Leica Microsystems,
Switzerland). Correct developmental stages were veri-
fied based on morphological features. For allele assess-
ment (Figure 2b,c), nematodes were mounted on slides,
and images were taken using an Axiovert 200 micro-
scope (Carl Zeiss, Jena, Germany) with a digital camera(C4742-98; Hamamatsu). Numbers of aggregates were
then quantified using a custom plugin (Dr Jesper S.
Pedersen; unpublished data) for ImageJ software (National
Institutes of Health). Aggregates in the head muscles were
counted above the border between pharynx and intestinal
valve.
To determine transgression, we compared the aggre-
gation range of the outlier RILs to the parental strains.
All the scored RIL 16 animals were in 4 to 16 aggregates
per animal range (see Additional file 2: Figure S2b),
more than 2SD away from the mean of the less aggre-
gated parent, Q40Bristol (mean ± SD 24.4 ± 3.7). Con-
versely, 88% of scored RIL 15 animals were in 63 to 80
aggregates per animal range, more than 2SD away from
the mean of the more aggregated parent, Q40DR1350
(51.5 ± 5.4=).
To measure the ratio between aggregated and soluble
polyQ40-YFP protein, native extracts were prepared as
described previously [6], incubated in 5% SDS at room
temperature, and resolved by non-denaturing PAGE.
Protein was visualized and quantified on Storm860 scan-
ner (Molecular Dynamics, USA) equipped with a blue
laser.
PolyQ-YFP protein levels in L1 animals, prior to the on-
set of aggregation, was determined by measuring YFP
fluorescence, normalized to the total protein concentra-
tion (bicinchoninic acid assay; Pierce, Rockford, IL, USA).
Briefly, embryos were collected by hypochlorite treatment,
hatched overnight in the absence of food to ensure
synchronization, and frozen at −80°C in aliquots. Lysates
were prepared by brief sonication followed by centrifuga-
tion at 14,000 × g. Expression levels of Q40-YFP in L1 ani-
mals of 20 RILs and two parental lines were within 50% of
each other.
Total polyQ40-YFP levels were quantified in L3 lar-
val animals by western blotting with goat anti-GFP
IRDye800 antibody (Rockland Immunochemicals, USA)
using Odyssey scanner (LI-COR, USA), in samples pre-
pared by boiling a known number of L3 larval animals
in 3% SDS. YFP levels were normalized to α-tubulin
with anti-α-tubulin primary antibody (Sigma,) followed
by Alexa Fluor 680 goat anti-mouse IgG (Molecular
Probes, USA). We chose L3 larvae in order to minimize
the effect of different turnover rates between aggregated
and soluble proteins between lines with suppressed and
enhanced aggregation, and boiling in SDS ensured com-
plete dissolution of aggregates.
Correlates of toxicity
Motility
To measure the number of bends per minute in swim-
ming animals, individual nematodes were picked into a
drop of M9 buffer, allowed to acclimate for 1 minute,
and then complete bends were counted for 1 minute. A
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anterior and posterior of the animal crossed the vertical
axis twice.MDI
To measure MDI, we modified the approach of Herndon
et al. [69] to provide a population-level measure of the
gradual decline in the muscle function of the same group
of animals over time. MDI and lifespan (see below) were
measured simultaneously in the same groups of animals.
Briefly, individual animals were given a score of 1 if they
moved unprovoked or moved rapidly after a gentle touch
with a pick or exposure to 1 to 2 seconds of blue light; a
score of 2 if they either moved slowly when unprovoked
or could move their entire body after gentle stimulation;
and a score of 3 if they were completely paralyzed or
could move only the head but not the body. The scores
were averaged over the number of animals tested to pro-
duce the MDI. At the extremes, MDI = 1 indicate that all
animals on the plate can move well, whereas MDI = 3
indicates that all animals are paralyzed.Internal hatching (bagging)
Animals were examined for internal hatching for the
duration of their reproductive period. In many cases,
one or only a few embryos were retained at the end of
reproduction, resulting in internal hatching but not the
typical ‘bag of worms’ appearance. One of the three trials
was performed simultaneously with lifespan/MDI on the
same group of animals.Lifespan
Animals were cultured on OP50 bacteria without fluoro-
uracil deoxyribose (FUdR), and transferred away from
their progeny every other day during reproductive period.
Animals were examined for signs of life initially daily and
then every 2 to 3 days by observing their movement. Ani-
mals that were not moving or twitching after gentle stimu-
lation, followed by vigorous stimulation, or that did not
exhibit pharyngeal pumping for 30 seconds, were con-
sidered dead. Animals that had internal hatching, or that
crawled off the plates, were censored. Data analysis was
performed as described by Yang et al. [80], using the pub-
licly available analysis suite Oasis [81].Statistics
All ANOVA and t-test analyses were performed using
Prism software (GraphPad, USA). ANOVA was followed
by multiple comparison post-test, either between se-
lected pairs, or between all groups, as indicated in the
figures, and α and significance levels are also indicated
in the figures.Additional files
Additional file 1: Figure S1. Muscle dysfunction is due to polyQ
expression. (a,b) Swimming motions (bends per minute) were scored in
(a) day 1 or (b) day 2 adult Q40Bristol and Q40DR1350 animals grown on
control (empty vector) or yellow fluorescent protein (YFP) RNA
interference (RNAi). YFP RNAi decreases expression of Q40-YFP fusion
protein, resulting in improvement in motility. YFP RNAi was partially
effective in a DR1350 background. (a) Q40Bristol animals had little loss of
motility on control plates at day 1, but had (b) a significant loss of
motility on day 2. (c) Motility of the non-transgenic parental strains, at
least 15 animals per genotype. (a, b) Independent experiments, 15 and
10 animals per treatment, respectively. (a, c) Data were analyzed by
ANOVA followed by Bonferroni’s multiple comparison test, α = 0.01,
**P>0.001 and <0.01, ***P<0.001. (b) Data were analyzed by unpaired t-
test, two-tailed, P<0.0001.
Additional file 2: Figure S2. Strains could be ranked according to
polyQ aggregation. (a) Lack of correlation between polyQ-YFP expression
levels in L1 animals and its aggregation across the recombinant inbred
lines (RILs). Aggregation data are the same as in Figure 2b. Data points in
color correspond to the selected RILs and parental strains as in panel (b).
(b) Statistical analysis of polyQ aggregation in selected strains. Each
symbol represents an individual animal, and data are the same as in
Figure 2b. RIL 16 represents a suppressed aggregation phenotype, ranked
as 1 for aggregation; RIL 10 is similar to Q40Bristol, both ranked as 2 to 3;
RIL 2 is similar to Q40DR1350, ranked as 4 to 5; and RILs 12(2) and 15
represent an enhanced aggregation phenotype, ranked as 6 to 7. Data
were analyzed by ANOVA followed by Bonferroni’s multiple comparison
test (all pair combinations), α = 0.01. The indicated pairs of strains are not
significantly different from each other, and all other combinations are
P<0.001. (c) Ratio of polyQ-yellow fluroescent protein (YFP) in SDS-
resistant high molecular weight and soluble monomeric species.
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